 This study investigates the activity of a new regimen of treatment for patients with metastatic colorectal carcinoma. This includes a combination of well-known chemotherapy agents and anti-inflammatory agents, when administered orally at low daily doses and without planed brakes Low Dose Metronomic regimen, in contrast with the conventional and already exhausted regimens of treatment at Maximal Tolerated Doses MTD which required pre-planned brakes between treatment days. 